LifeSci Capital
LifeSci Capital is a New York-based boutique investment bank focused exclusively on life sciences. Its research analysts hold advanced scientific or medical degrees, and the firm provides capital markets and advisory services to biotechnology, pharmaceutical and medical-technology companies.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 212M
- Actions
- 212M
- Ratings / Price targets
- 2 / 0
- Upgrades / Downgrades
- 0 / 2
- Buy-rated
- 0%of 2 rated
- On record
- Apr 2023 – Jun 2026
Overview
As of 2026, LifeSci Capital covers 92 life-science companies with an average market capitalization of about $2.3 billion. Its main research offerings are the Alpha Series of detailed analyses informed by experts and the KOL Series of events with leading medical specialists. The firm says its research and non-deal roadshows aim to make covered companies more visible to investors.
Michael Rice and Andrew McDonald, former ThinkEquity Partners colleagues who co-founded investor-relations firm LifeSci Advisors in 2010, founded LifeSci Capital as a New York broker-dealer in 2013. It launched its Alpha Series research product in June 2018. LifeSci Acquisition Corp., a SPAC whose sponsor was affiliated with the firm, merged with Vincera Pharma, later Vincerx Pharma, in December 2020. McDonald serves as chief executive and Rice as president.
Milestones
- 2013
LifeSci Capital founded as a New York broker-dealer
- 2018
Launches Alpha Series equity research product
- 2020
Affiliate-sponsored LifeSci Acquisition Corp. merges with Vincera Pharma
Firm facts
- Legal name
- LifeSci Capital LLC
- Type
- Boutique
- Founded
- 2013
- Headquarters
- New York, United States
- Chief Executive Officer and Co-Founder
- Andrew McDonald
- Director of Research
- Adam Evertts
- Rating scale
- OutperformMarket PerformUnderperform12 months
- Website
- lifescicapital.com
Research philosophy
Our team is highly selective in choosing companies to cover, focusing on innovative science, disruptive clinical data, and capable management teams.
LifeSci Capital calls expert engagement the core of its research process, drawing on investor calls and dinners with medical experts, physician surveys and coverage of major medical meetings. In January 2020 it announced a move to fully independent, high-conviction coverage of selected companies.
Rating methodology
Its 12-month ratings are Outperform, Market Perform and Underperform, with Outperform indicating an expected total return of at least 15% and Underperform a loss of at least 10%.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 Abivax S.A.ABVX | Outperform | — |
 Mereo BioPharma Group plcMREO | Market Perform | — |
| NUNuvalent, Inc.NUVL | Market Perform | — |
Recent actions
| Date | Stock | Rating action | Rating |
|---|---|---|---|
| Jun 9 | NUNuvalent, Inc.NUVL | Downgrade | Outperform →Market Perform |
| Dec 29, 2025 | Mereo BioPharma Group plcMREO | Downgrade | Outperform →Market Perform |
| Jul 23, 2025 | Abivax S.A.ABVX | Reiterate | Outperform |
| Apr 5, 2023 | IFInflaRx N.V.IFRX | Upgrade | Market Perform →Outperform |